SLC5A2 and Hypoglycemia: Due to their insulin-independent mechanism of action, SGLT2 inhibitors are also associated with a low risk of hypoglycemic episodes when they are used as monotherapy or in combination with other AHAs not associated with a high risk of hypoglycemia (sulfonylureas and insulins can induce hypoglycemia) [17, 18].